MA39952B1 - Programme de traitement pour composé de tiacumicin - Google Patents
Programme de traitement pour composé de tiacumicinInfo
- Publication number
- MA39952B1 MA39952B1 MA39952A MA39952A MA39952B1 MA 39952 B1 MA39952 B1 MA 39952B1 MA 39952 A MA39952 A MA 39952A MA 39952 A MA39952 A MA 39952A MA 39952 B1 MA39952 B1 MA 39952B1
- Authority
- MA
- Morocco
- Prior art keywords
- days
- tiacumicin
- clostridium difficile
- tiacumicin compound
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci, et une composition pharmaceutique contenant un composé de tiacumicine, un stéréoisomère, un polymorphe ou un solvate pharmaceutiquement acceptable de celui-ci. Dans le traitement oral d'infections à clostridium difficile (cdi) ou de diarrhée ou maladie associée à clostridium difficile (cda) chez un patient conformément à un schéma posologique choisi dans le groupe comprenant: i. Administration de 200 mg du composé de tiacumicine bid pendant 5 jours suivis de 5 jours de repos, puis de 200 mg une fois par jour pendant 10 jours supplémentaires et ii. Administration de 200 mg du composé de tiacumicine bid pendant 5 jours, suivie d’une dose unique de 200 mg tous les deux jours pendant 20 jours. En outre, la présente invention concerne un procédé permettant de récupérer une population intestinale de bifidobactéries chez un patient souffrant d’infections à clostridium difficile (cdi) ou de diarrhée ou maladie associée à clostridium difficile (cd ad) et à recevoir un traitement par voie orale avec un composé de tiacumicine jusqu'à 50 à 90% des cas. La population intestinale de bifidobactéries avant l'administration du composé de tiacumicine pendant les jours 15 à 45 après le début du traitement, en administrant par voie orale le composé de tiacumicine au patient selon un schéma posologique choisi dans le groupe susmentionné.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14075031 | 2014-05-09 | ||
| PCT/EP2015/000965 WO2015169451A1 (fr) | 2014-05-09 | 2015-05-11 | Composé de tiacumicine et régime de traitement associé |
| EP15731245.5A EP3139932B1 (fr) | 2014-05-09 | 2015-05-11 | Programme de traitement pour composé de tiacumicin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39952A MA39952A (fr) | 2017-03-15 |
| MA39952B1 true MA39952B1 (fr) | 2018-12-31 |
Family
ID=50771031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39952A MA39952B1 (fr) | 2014-05-09 | 2015-05-11 | Programme de traitement pour composé de tiacumicin |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10137141B2 (fr) |
| EP (1) | EP3139932B1 (fr) |
| JP (1) | JP6579662B2 (fr) |
| KR (1) | KR20160149288A (fr) |
| AU (1) | AU2015258130B2 (fr) |
| CA (1) | CA2948400A1 (fr) |
| CY (1) | CY1120847T1 (fr) |
| DK (1) | DK3139932T3 (fr) |
| EA (1) | EA031756B1 (fr) |
| ES (1) | ES2694028T3 (fr) |
| GE (1) | GEP20186872B (fr) |
| HR (1) | HRP20181756T1 (fr) |
| IL (1) | IL248782B (fr) |
| LT (1) | LT3139932T (fr) |
| MA (1) | MA39952B1 (fr) |
| MD (1) | MD4695C1 (fr) |
| PL (1) | PL3139932T3 (fr) |
| PT (1) | PT3139932T (fr) |
| RS (1) | RS57994B1 (fr) |
| SI (1) | SI3139932T1 (fr) |
| TR (1) | TR201815891T4 (fr) |
| UA (1) | UA122203C2 (fr) |
| WO (1) | WO2015169451A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316892B1 (fr) * | 2015-07-03 | 2023-07-19 | Tillotts Pharma AG | Composé de tiacumicin avec un nouveau régime posologique |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| US7507564B2 (en) | 2002-07-29 | 2009-03-24 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| LT2305245T (lt) * | 2004-05-14 | 2019-03-12 | Merck Sharp & Dohme Corp. | Su antibiotikų vartojimu susijusių ligų gydymas |
| MX340742B (es) | 2005-01-31 | 2016-07-21 | Merck Sharp & Dohme | Compuestos macrociclicos de 18 miembros y analogos de los mismos. |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| CN102030791B (zh) | 2010-10-28 | 2013-01-23 | 中国科学院南海海洋研究所 | 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用 |
| CN102115757B (zh) | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
| WO2013138748A1 (fr) * | 2012-03-16 | 2013-09-19 | Optimer Pharmaceuticals, Inc. | Prévention d'infection par clostridium difficile chez des patients à haut risque |
| JO3464B1 (ar) * | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
-
2015
- 2015-05-11 US US15/309,992 patent/US10137141B2/en not_active Expired - Fee Related
- 2015-05-11 DK DK15731245.5T patent/DK3139932T3/en active
- 2015-05-11 PT PT15731245T patent/PT3139932T/pt unknown
- 2015-05-11 KR KR1020167034087A patent/KR20160149288A/ko not_active Application Discontinuation
- 2015-05-11 SI SI201530443T patent/SI3139932T1/sl unknown
- 2015-05-11 UA UAA201610790A patent/UA122203C2/uk unknown
- 2015-05-11 WO PCT/EP2015/000965 patent/WO2015169451A1/fr active Application Filing
- 2015-05-11 EA EA201692107A patent/EA031756B1/ru unknown
- 2015-05-11 AU AU2015258130A patent/AU2015258130B2/en not_active Ceased
- 2015-05-11 PL PL15731245T patent/PL3139932T3/pl unknown
- 2015-05-11 CA CA2948400A patent/CA2948400A1/fr not_active Abandoned
- 2015-05-11 MA MA39952A patent/MA39952B1/fr unknown
- 2015-05-11 JP JP2016567190A patent/JP6579662B2/ja active Active
- 2015-05-11 ES ES15731245.5T patent/ES2694028T3/es active Active
- 2015-05-11 LT LTEP15731245.5T patent/LT3139932T/lt unknown
- 2015-05-11 RS RS20181271A patent/RS57994B1/sr unknown
- 2015-05-11 MD MDA20160131A patent/MD4695C1/ro active IP Right Grant
- 2015-05-11 GE GEAP201514327A patent/GEP20186872B/en unknown
- 2015-05-11 EP EP15731245.5A patent/EP3139932B1/fr active Active
- 2015-05-11 TR TR2018/15891T patent/TR201815891T4/tr unknown
-
2016
- 2016-11-06 IL IL248782A patent/IL248782B/en active IP Right Grant
-
2018
- 2018-10-24 HR HRP20181756TT patent/HRP20181756T1/hr unknown
- 2018-10-30 CY CY181101119T patent/CY1120847T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160149288A (ko) | 2016-12-27 |
| CY1120847T1 (el) | 2019-12-11 |
| MA39952A (fr) | 2017-03-15 |
| HRP20181756T1 (hr) | 2018-12-28 |
| SI3139932T1 (sl) | 2018-12-31 |
| LT3139932T (lt) | 2018-11-12 |
| MD20160131A2 (ro) | 2017-05-31 |
| IL248782B (en) | 2020-08-31 |
| IL248782A0 (en) | 2017-01-31 |
| RS57994B1 (sr) | 2019-01-31 |
| EP3139932A1 (fr) | 2017-03-15 |
| AU2015258130A1 (en) | 2016-12-15 |
| DK3139932T3 (en) | 2018-11-12 |
| ES2694028T3 (es) | 2018-12-17 |
| EA031756B1 (ru) | 2019-02-28 |
| TR201815891T4 (tr) | 2018-11-21 |
| GEP20186872B (en) | 2018-06-25 |
| CA2948400A1 (fr) | 2015-11-12 |
| MD4695B1 (ro) | 2020-05-31 |
| UA122203C2 (uk) | 2020-10-12 |
| EA201692107A1 (ru) | 2017-04-28 |
| PL3139932T3 (pl) | 2019-02-28 |
| WO2015169451A1 (fr) | 2015-11-12 |
| JP2017514880A (ja) | 2017-06-08 |
| EP3139932B1 (fr) | 2018-08-01 |
| PT3139932T (pt) | 2018-11-14 |
| JP6579662B2 (ja) | 2019-09-25 |
| AU2015258130B2 (en) | 2019-10-31 |
| US10137141B2 (en) | 2018-11-27 |
| MD4695C1 (ro) | 2021-02-28 |
| US20170143750A1 (en) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41197B1 (fr) | Traitement de le pemphigus | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| Paoluzi et al. | Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study | |
| MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
| JP2010535767A5 (fr) | ||
| WO2008085484A3 (fr) | Procédé de traitement de l'affection abdominale inflammatoire | |
| JP2019530706A5 (fr) | ||
| JP2017525713A5 (fr) | ||
| JP2018039810A5 (fr) | ||
| Trauner et al. | Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies | |
| Tillmann et al. | Behavioral and metabolic effects of S-adenosylmethionine and imipramine in the Flinders Sensitive Line rat model of depression | |
| MA39952B1 (fr) | Programme de traitement pour composé de tiacumicin | |
| Siarkos et al. | A review of pharmacological treatments for depression in Alzheimer’s disease | |
| Bhatt et al. | Protective effects of a novel 5-HT3 receptor antagonist, Nn-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronic unpredictable mild stress-induced behavioral changes and biochemical alterations | |
| AU2022387121A1 (en) | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders | |
| Prados et al. | A population pharmacokinetic approach to describe cephalexin disposition in adult and aged dogs | |
| FR2899111B1 (fr) | Concentre d'immunoglobulines specifiques du chikungunya en tant que medicament. | |
| AU2018258970B2 (en) | Idalopirdine-based combinatorial therapies of Alzheimer's disease | |
| Do et al. | Drug-Induced Acneiform Eruptions | |
| Seeman et al. | Antipsychotic dosing: extended, and transient | |
| Prendecki | Cushingoid: case report | |
| Qu | Neurotropin/pregabalin/topiramate | |
| RU2016145411A (ru) | Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости | |
| Detke et al. | A phase 1b study of potential safety and pharmacokinetic interactions between ***e and EMB-001, with exploratory efficacy measures | |
| Sutrisna | Current treatment of irritable bowel syndrome. |